PRQR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ProQR Therapeutics NV (PRQR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has potential due to its RNA editing platform and positive analyst sentiment, the technical indicators are bearish, and the financial performance shows declining revenue and profitability. The lack of recent news or significant trading trends further suggests no immediate catalysts for growth. It is better to monitor the stock for now.
The technical indicators for PRQR are bearish. The MACD is negatively expanding, RSI is neutral at 34.49, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.644, with key support at 1.491 and resistance at 1.797.
Analyst coverage by Oppenheimer with an Outperform rating and a $9 price target, citing strong preclinical data and potential to address unmet medical needs.
Declining financial performance in Q3 2025, with revenue dropping by 26.78% YoY and gross margin falling to 0%. No recent news, congress trading data, or significant insider/hedge fund activity.
In Q3 2025, revenue dropped by 26.78% YoY to $2,915,000. Net income improved by 35.74% YoY but remains negative at -$11,006,000. EPS and gross margin both dropped to 0, indicating weak financial health.
Oppenheimer analyst Kostas Biliouris initiated coverage with an Outperform rating and a $9 price target, highlighting strong preclinical data and the company's potential to address unmet needs in specific medical conditions.
